Lampropoulos Konstantinos, Megalou Aikaterini, Bazoukis George, Tse Gary, Manolis Antonios
Department of Cardiology, Evangelismos General Hospital of Athens, Athens, Greece.
Department of Medicine and Therapeutics, Chinese University of Hong Kong, Li Ka Shing Institute of Health Sciences, Hong Kong, SAR, P.R. China.
J Interv Cardiol. 2017 Dec;30(6):507-513. doi: 10.1111/joic.12421. Epub 2017 Aug 7.
Statins constitute the most powerful class of drugs for cardiovascular risk reduction associated to atherosclerosis. Their important pharmacological properties include reduction of serum lipid concentrations and non-lipid related, pleotropic effects such as anti-inflammatory action. Previous largescale randomized studies have demonstrated the beneficial effects of statin loading prior to elective percutaneous coronary intervention (PCI) for the reduction of periprocedural myocardial infarction and prevention of major adverse cardiac events at 30 days. The present review summarizes the data from major randomized trials that evaluated the clinical benefit of statin pretreatment in the setting of PCI resulting in a better understanding of their impact on reduction of interventional complications.
他汀类药物是降低与动脉粥样硬化相关的心血管风险最有效的一类药物。其重要的药理学特性包括降低血脂浓度以及非脂质相关的多效性作用，如抗炎作用。以往的大规模随机研究表明，在择期经皮冠状动脉介入治疗（PCI）前给予负荷量他汀类药物，可减少围手术期心肌梗死，并预防30天时的主要不良心脏事件。本综述总结了主要随机试验的数据，这些试验评估了PCI时他汀类药物预处理的临床益处，从而更好地理解其对减少介入并发症的影响。
